Skip to search formSkip to main contentSkip to account menu

AFQ056

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

mavoglurant

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Assessment of the pulmonary CYP1A1 metabolism of mavoglurant (AFQ056) in rat
Abstract 1. AFQ056 phenotyping results indicate that CYP1A1 is responsible for the formation of the oxidative metabolite, M3. In… 
2015
2015
Effect of mavoglurant (AFQ056), a selective mGluR5 antagonist, on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and levonorgestrel in healthy women.
OBJECTIVE To compare the pharmacokinetics (PKs) of a combination oral contraceptive (OC) when given alone or concomitantly with… 
2013
2013
Neurophysiological signals as potential translatable biomarkers for modulation of metabotropic glutamate 5 receptors
Review
2013
Review
2013
Progress toward therapeutic potential for AFQ056 in Fragile X syndrome
Fragile X syndrome (FXS) is the most common form of inherited intellectual disability and the leading single-gene cause of autism… 
2013
2013
PP245—In-vitro bioassay of 1,5 - dimethyl citrate monohydrate; a compound isolated from the fruit of mangifera Indica (anacardiaceae)
2012
2012
The mGluR5 antagonist AFQ056 does not affect methylation and transcription of the mutant FMR1 gene in vitro
BackgroundFragile X syndrome (FXS), the leading cause of inherited mental retardation, is due to expansion and methylation of a… 
2012
2012
Understanding and Prevention of “Therapy-” Induced Dyskinesias
L-dopa is the most effective, currently available treatment for Parkinson's disease (PD), but it leads to the development of… 
2012
2012
Validation of an LC-MS/MS method for the quantitative determination of mavoglurant (AFQ056) in human plasma
A simple, sensitive, and selective liquid chromatography/tandem mass spectrometry method was validated for the identification and… 
2011
2011
Epigenetic modification of the FMR1 gene in fragile X patients leads to a differential response to the mGluR5 antagonist AFQ056
Fragile X syndrome (FXS) is an X-linked condition associated with intellectual disability and behavioral problems. It is caused… 
2006
2006
Use of mglur5 (esp. afq056) in gi (esp. gerd)
The present invention is the use of a compound which acts as a mGluR5 antagonist in the gastrointestinal tract disorders, urinary… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)